Login to Your Account



AAVLife series A: $12M for Friedreich's ataxia gene therapy program

By Randy Osborne
Staff Writer

Tuesday, April 15, 2014
About 13 years ago, when Amber Salzman's son and two nephews were diagnosed with adrenoleukodystrophy (ALD), a genetic brain disorder, she didn't know much about rare diseases at all. That's changed for the CEO of Paris-based AAVLife, which – with $12 million in series A money – is taking aim at another: Friedreich's ataxia (FA).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription